10 Recruiting Studies Using Larotrectinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Larotrectinib
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
Central Nervous System Neoplasm
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
📍 Children's Hospital Los Angeles - Hematology/Oncology — Los Angeles, California
Solid Tumors Harboring NTRK Fusion
View Study & Checklist ➔Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
📍 Children's Hospital Colorado — Aurora, Colorado
High Grade Glioma
View Study & Checklist ➔Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
📍 Banner Desert Medical Center — Mesa, Arizona
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
View Study & Checklist ➔Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
📍 University of California, San Francisco — San Francisco, California
Differentiated Thyroid Cancer
View Study & Checklist ➔Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
Locally Advanced Malignant Solid Neoplasm
View Study & Checklist ➔